NBIX logo

Neurocrine Biosciences Inc. (NBIX)

$165.31

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on NBIX

Market cap

$16.73B

EPS

6.75

P/E ratio

20.8

Price to sales

4.29

Dividend yield

--

Beta

0.362101

Price on NBIX

Previous close

$167.40

Today's open

$168.39

Day's range

$164.81 - $168.62

52 week range

$122.14 - $186.12

Profile about NBIX

CEO

Kyle W. Gano

Employees

2000

Headquarters

San Diego, CA

Exchange

Nasdaq Global Select

Shares outstanding

101218643

Issue type

Common Stock

NBIX industries and sectors

Healthcare

Pharmaceuticals

News on NBIX

Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • 11 hours ago

news preview

Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

news source

Zacks Investment Research • Nov 16, 2026

news preview

Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

SAN DIEGO, Nov. 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the 2026 Jefferies Global Healthcare Conference in London at 3:30 p.m. Greenwich Mean Time (10:30 a.m.

news source

PRNewsWire • Nov 10, 2026

news preview

NBIX or GRDN: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX) and Guardian Pharmacy Services (GRDN). But which of these two stocks presents investors with the better value opportunity right now?

news source

Zacks Investment Research • Nov 10, 2026

news preview

Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 25.5% in Neurocrine (NBIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

news source

Zacks Investment Research • Nov 9, 2026

news preview

All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy

Neurocrine (NBIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

news source

Zacks Investment Research • Nov 9, 2026

news preview

Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice

Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.

news source

Zacks Investment Research • Nov 9, 2026

news preview

NBIX vs. GRDN: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Drugs sector might want to consider either Neurocrine Biosciences (NBIX) or Guardian Pharmacy Services (GRDN). But which of these two companies is the best option for those looking for undervalued stocks?

news source

Zacks Investment Research • Nov 9, 2026

news preview

Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules

Survey reveals work or school disruptions among adults with tardive dyskinesia declined from 57% before treatment to 21% after starting INGREZZA, with average missed days per month decreasing from 5.6 to 2.0 A separate post-hoc analysis of KINECT-PRO™ data showed patient-reported improvement with INGREZZA across all six physical and socio-emotional areas assessed by the Tardive Dyskinesia Impact Scale (TDIS™) among participants reporting impacts to those areas at baseline SAN DIEGO, Nov. 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey showing that adults with tardive dyskinesia (TD) reported fewer disruptions to work and school after starting treatment with INGREZZA® (valbenazine) capsules.1 A separate post-hoc analysis of the KINECT-PRO™ Phase 4 open-label study showed robust patient-reported improvement with INGREZZA across all six physical and socio-emotional areas measured by the Tardive Dyskinesia Impact Scale (TDIS™) among participants who reported impacts in those areas at baseline. The TDIS is the only psychometrically validated tool that measures the burden of TD from a patient's perspective.

news source

PRNewsWire • Nov 5, 2026

news preview

Neurocrine Biosciences: Breaking Down A Solid Quarter

Neurocrine Biosciences delivered robust Q3 results Monday after the bell, with EPS of $3.29 and revenue up 41% to $1.12 billion. INGREZZA remains NBIX's primary growth driver, posting 17% year-over-year sales growth to $801 million on strong volume gains. The Soleno Therapeutics acquisition and VYKAT XR approval expand NBIX's rare disease portfolio, with VYKAT XR showing strong initial adoption.

news source

Seeking Alpha • Nov 5, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Neurocrine Biosciences Inc.

Open an M1 investment account to buy and sell Neurocrine Biosciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in NBIX on M1